









Markets
/
Stocks
/
nasdaq-vyne
/

Vyne Therapeutics Inc

VYNE

0.322USD

-0.005-1.65%

Close 11/04, 16:00（ET）Quotes delayed by 15 min

6.37MMarket Cap

LossP/E TTM



Vyne Therapeutics Inc

0.322

-0.005-1.65%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Vyne Therapeutics Inc

Currency: USD Updated: 2025-11-04

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Vyne Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

192 / 407

Overall Ranking

327 / 4616

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 4 analysts

Buy

Current Rating

3.250

Target Price

+838.76%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Vyne Therapeutics Inc Highlights

StrengthsRisks

VYNE Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing differentiated therapies for the treatment of immuno-inflammatory conditions. Its product candidate is VYN201, a locally administered pan-BET inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, a BD2-selective oral small molecule bromodomain and extra-terminal (BET) inhibitor in preclinical development for the treatment of immuno-inflammatory indications. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.

Growing

The company is in a growing phase, with the latest annual income totaling USD 501.00K.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 501.00K.

Fairly Valued

The company’s latest PE is -0.36, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 8.80M shares, decreasing 6.25% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 496.30K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 2.76.

Financial Health

Currency: USD Updated: 2025-11-04

The company's current financial score is 6.46, which is lower than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 69.00K, representing a year-over-year decrease of 65.15%, while its net profit experienced a year-over-year decrease of 38.82%.

Score

Industry at a Glance

Previous score

6.46

Change



Financials

9.13

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

8.61

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.57

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

4.90

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.11

Key Metrics

Free cash flow

No Data

Vyne Therapeutics Inc's Company Valuation

Currency: USD Updated: 2025-11-04

The company’s current valuation score is 6.98, which is lower than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -0.36, which is -472.85% below the recent high of 1.35 and -1162.69% above the recent low of -4.58.

Score

Industry at a Glance

Previous score

6.98

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 192/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-04

The company’s current earnings forecast score is 7.00, which is lower than the Biotechnology & Medical Research industry's average of 8.00. The average price target for Vyne Therapeutics Inc is 3.25, with a high of 4.50 and a low of 2.00.

Score

Industry at a Glance

Previous score

7.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 4 analysts

Buy

Current Rating

3.250

Target Price

+838.76%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Vyne Therapeutics Inc

VYNE

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-04

The company’s current price momentum score is 5.13, which is lower than the Biotechnology & Medical Research industry's average of 6.41. Sideways: Currently, the stock price is trading between the resistance level at 0.41 and the support level at 0.28, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

4.71

Change

0.42

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(1)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.006

Sell

RSI(14)

41.053

Neutral

STOCH(KDJ)(9,3,3)

19.565

Sell

ATR(14)

0.028

Low Volatility

CCI(14)

-194.319

Sell

Williams %R

96.734

Oversold

TRIX(12,20)

0.032

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

0.349

Sell

MA10

0.355

Sell

MA20

0.369

Sell

MA50

0.341

Sell

MA100

0.636

Sell

MA200

1.215

Sell

Institutional Confidence

Currency: USD Updated: 2025-11-04

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.15. The latest institutional shareholding proportion is 34.54%, representing a quarter-over-quarter decrease of 39.15%. The largest institutional shareholder is The Vanguard, holding a total of 496.30K shares, representing 1.95% of shares outstanding, with 39.18% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Cormorant Asset Management, LP

1.37M

Access Industries, Inc.

1.12M

Citadel Advisors LLC

1.04M

-5.48%

Acorn Capital Advisors, LLC

736.57K

-6.28%

Delaware Street Capital, L.L.C.

696.47K

Adage Capital Management, L.P.

644.13K

+87.18%

Dafna Capital Management, LLC

636.10K

Kennedy Capital Management LLC

570.74K

+631.35%

The Vanguard Group, Inc.

Star Investors

496.30K

+4.34%

Palo Alto Investors LP

445.43K

Risk Assessment

Currency: USD Updated: 2025-11-04

The company’s current risk assessment score is 1.26, which is lower than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 2.01. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.